Free tool
FAERS Monitor: Uroxatral
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 021287 or its brand name (Uroxatral, Alfuzosin Hydrochloride). Reports on generic versions are filed under their own applications.
Reports
3,374
Serious
1,950
58% of reports
Hospitalization
1,001
Death reported
242
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- dizziness252
- drug ineffective206
- fatigue200
- dyspnoea145
- asthenia132
- nausea132
- fall126
- diarrhoea124
- headache119
- hypotension102
- syncope97
- insomnia94
- malaise92
- pain90
- back pain86
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 279 |
| 2005 | 270 |
| 2006 | 180 |
| 2007 | 129 |
| 2008 | 140 |
| 2009 | 183 |
| 2010 | 301 |
| 2011 | 312 |
| 2012 | 275 |
| 2013 | 103 |
| 2014 | 87 |
| 2015 | 177 |
| 2016 | 196 |
| 2017 | 163 |
| 2018 | 127 |
| 2019 | 102 |
| 2020 | 117 |
| 2021 | 95 |
| 2022 | 30 |
| 2023 | 23 |
| 2024 | 31 |
| 2025 | 32 |
| 2026 | 22 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,050,785 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| syncopeSignal | 97 | 6.0 | 5.0 | 405 |
| hypotensionSignal | 102 | 3.2 | 2.6 | 151 |
| dizzinessSignal | 252 | 3.2 | 2.8 | 377 |
| fallSignal | 126 | 2.4 | 2.0 | 99 |
| back painSignal | 86 | 2.3 | 1.9 | 63 |
| insomniaSignal | 94 | 2.2 | 1.8 | 61 |
| astheniaSignal | 132 | 2.2 | 1.9 | 86 |
| fatigue | 200 | 1.6 | 1.4 | 46 |
| dyspnoea | 145 | 1.6 | 1.4 | 33 |
| malaise | 92 | 1.3 | 1.1 | 6 |
| diarrhoea | 124 | 1.2 | 1.0 | 4 |
| headache | 119 | 1.2 | 1.0 | 3 |
| nausea | 132 | 1.0 | 0.9 | 0 |
| drug ineffective | 206 | 1.0 | 0.9 | 0 |
| pain | 90 | 0.9 | 0.7 | 1 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.